Aptiv PLC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aptiv PLC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.15B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $4.91B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $4.92B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $4.64B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $4.13B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $4.21B | Feb 7, 2022 |
| FY2020 | Sep 30, 2020 | $3.67B | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $1.96B | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $3.23B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $3.60B | Feb 8, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.40B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $19.71B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $20.05B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $17.49B | Feb 7, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $963.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $962.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $922.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $813.00M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $591.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $779.00M | Feb 7, 2022 |
| FY2020 | Sep 30, 2020 | $647.00M | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $13.00M | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $501.00M | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $687.00M | Feb 8, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $268.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $905.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $249.00M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $31.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $299.00M | Feb 7, 2022 |
| FY2020 | Sep 30, 2020 | $299.00M | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | ($366.00M) | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $1.57B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $230.00M | Feb 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $425.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $479.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $355.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $440.00M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $260.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $446.00M | Feb 7, 2022 |
| FY2020 | Sep 30, 2020 | $364.00M | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | ($311.00M) | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $1.62B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $324.00M | Feb 8, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.29B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $1.12B | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $1.03B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $1.02B | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $1.17B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.16B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $882.00M | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $800.00M | Feb 4, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.67B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.47B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.44B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $1.14B | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $1.08B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $976.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $1.08B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $993.00M | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $952.00M | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $924.00M | Feb 4, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.19B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.45B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.90B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $1.26B | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $1.22B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $1.41B | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $1.62B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.63B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $1.47B | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $1.94B | Feb 4, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $844.00M | Feb 8, 2023 |
| FY2022 | Dec 31, 2021 | $611.00M | Feb 8, 2023 |
| FY2022 | Dec 31, 2020 | $584.00M | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $781.00M | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $846.00M | Feb 8, 2021 |
| FY2018 | Dec 31, 2017 | $698.00M | Feb 4, 2019 |
| FY2018 | Dec 31, 2016 | $657.00M | Feb 4, 2019 |
| FY2017 | Dec 31, 2015 | $503.00M | Feb 5, 2018 |
| FY2016 | Dec 31, 2014 | $779.00M | Feb 6, 2017 |
| FY2015 | Dec 31, 2013 | $605.00M | Feb 8, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.41B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $23.46B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $24.43B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $21.88B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $18.01B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $17.52B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $13.46B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $12.48B | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $12.17B | Feb 4, 2019 |
| FY2017 | Dec 31, 2016 | $12.29B | Feb 5, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.91B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $14.37B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $12.58B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $12.79B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $9.45B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $9.42B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $9.45B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $8.81B | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $8.65B | Feb 4, 2019 |
| FY2017 | Dec 31, 2016 | $9.53B | Feb 5, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.21B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $8.80B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $11.55B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $8.81B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $8.35B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $7.91B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.82B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $3.46B | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $3.30B | Feb 4, 2019 |
| FY2017 | Dec 31, 2016 | $2.40B | Feb 5, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.60B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.02B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $5.15B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $5.11B | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $2.51B | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $2.58B | Feb 8, 2023 |
| FY2021 | Dec 31, 2019 | $2.41B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $2.52B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $1.94B | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $1.50B | Feb 4, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.23B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $7.00B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $8.16B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $5.61B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $5.08B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $4.55B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $2.89B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $2.51B | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $2.12B | Feb 4, 2019 |
| FY2017 | Dec 31, 2016 | $1.98B | Feb 5, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.85B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.57B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $1.64B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.53B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $3.14B | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | $2.82B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $412.00M | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $567.00M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $1.60B | Feb 4, 2019 |
| FY2017 | Dec 31, 2016 | $737.00M | Feb 5, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.65B | Feb 6, 2026 |
| FY2024 | Dec 31, 2024 | $8.47B | Feb 7, 2025 |
| FY2023 | Dec 31, 2023 | $6.30B | Feb 6, 2024 |
| FY2022 | Dec 31, 2022 | $6.58B | Feb 8, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 3 | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | 1 | Feb 7, 2022 |
| FY2020 | Sep 30, 2020 | 1 | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | 6 | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 8, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 3 | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | 1 | Feb 7, 2022 |
| FY2020 | Sep 30, 2020 | 1 | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | 6 | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 8, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 212.75M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 235.04M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 279.03M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | 270.95M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | 270.51M | Feb 8, 2023 |
| FY2021 | Dec 31, 2020 | 270.03M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | 255.29M | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | 259.99M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | 265.84M | Feb 4, 2019 |
| FY2017 | Dec 31, 2016 | 269.79M | Feb 5, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Feb 8, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Feb 7, 2022 |
| FY2021 | Sep 30, 2021 | $0 | Feb 7, 2022 |
| FY2021 | Jun 30, 2021 | $0 | Feb 7, 2022 |
| FY2021 | Mar 31, 2021 | $0 | Feb 7, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Feb 7, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Feb 7, 2022 |
| FY2021 | Jun 30, 2020 | $0 | Feb 7, 2022 |
| FY2021 | Mar 31, 2020 | $56.00M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $56.00M | Feb 8, 2021 |